This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brueggemann, A. B.
Right arrow Articles by Doern, G. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brueggemann, A. B.
Right arrow Articles by Doern, G. V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Jul 1997, 1594-1597, Vol 41, No. 7
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

AB Brueggemann, KC Kugler and GV Doern
Clinical Microbiology Laboratories, University of Massachusetts Medical Center, Worcester 01655, USA.

The in vitro activity of a novel 8-methoxyquinolone, BAY 12-8039, against recent clinical isolates of Streptococcus pneumoniae (n = 404), Haemophilus influenzae (n = 330), and Moraxella catarrhalis (n = 250) was evaluated. Activity was compared to those of six other fluoroquinolones: ciprofloxacin, clinafloxacin, levofloxacin, ofloxacin, sparfloxacin and trovafloxacin. BAY 12-8039 and clinafloxacin had the highest levels of activity against S. pneumoniae, both with a MIC at which 90% of the isolates were inhibited (MIC90) of 0.06 microg/ml. Trovafloxacin and sparfloxacin were the next most active agents versus S. pneumoniae (MIC90s = 0.12 microg/ml). No differences in activity against penicillin-susceptible, -intermediate, or -resistant strains of S. pneumoniae were noted for any of the fluoroquinolones tested. MIC90s for the seven fluoroquinolones ranged from 0.008 to 0.06 microg/ml versus H. influenzae and from 0.008 to 0.12 microg/ml for M. catarrhalis. The MICs for two strains of S. pneumoniae and one strain of H. influenzae were noted to be higher than those for the general population of organisms for all of the fluoroquinolones tested. Finally, the activity of BAY 12-8039 versus S. pneumoniae was found to be diminished when MIC determinations were performed with incubation of agar dilution plates or broth microdilution trays in 5 to 7% CO2 versus ambient air.


This article has been cited by other articles:

  • Batard, E., Juvin, M. E., Jacqueline, C., Bugnon, D., Caillon, J., Potel, G., Drugeon, H. B. (2005). Influence of Carbon Dioxide on the MIC of Telithromycin for Streptococcus pneumoniae: an In Vitro-In Vivo Study. Antimicrob. Agents Chemother. 49: 464-466 [Abstract] [Full Text]  
  • Bronner, S., Jehl, F., Peter, J.-D., Ploy, M.-C., Renault, C., Arvis, P., Monteil, H., Prevost, G. (2003). Moxifloxacin Efficacy and Vitreous Penetration in a Rabbit Model of Staphylococcus aureus Endophthalmitis and Effect on Gene Expression of Leucotoxins and Virulence Regulator Factors. Antimicrob. Agents Chemother. 47: 1621-1629 [Abstract] [Full Text]  
  • Gehanno, P., Darantiere, S., Dubreuil, C., Chobaut, J. C., Bobin, S., Pages, J. C., Renou, G., Bobin, F., Arvis, P., Stass, H. (2002). A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 49: 821-826 [Abstract] [Full Text]  
  • Lister, P. D. (2002). Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model: Impact of Area under the Curve/MIC Ratios on Eradication. Antimicrob. Agents Chemother. 46: 69-74 [Abstract] [Full Text]  
  • Guthrie, R. (2001). Community-Acquired Lower Respiratory Tract Infections : Etiology and Treatment. Chest 120: 2021-2034 [Abstract] [Full Text]  
  • Fischer, S., Adam, D. (2001). Effects of Moxifloxacin on Neutrophil Phagocytosis, Burst Production, and Killing as Determined by a Whole-Blood Cytofluorometric Method. Antimicrob. Agents Chemother. 45: 2668-2669 [Full Text]  
  • Coyle, E. A., Kaatz, G. W., Rybak, M. J. (2001). Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 1654-1659 [Abstract] [Full Text]  
  • Hamamoto, K., Shimizu, T., Fujimoto, N., Zhang, Y., Arai, S. (2001). In Vitro Activities of Moxifloxacin and Other Fluoroquinolones against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 45: 1908-1910 [Abstract] [Full Text]  
  • Jones, M. E., Staples, A. M., Critchley, I., Thornsberry, C., Heinze, P., Engler, H. D., Sahm, D. F. (2000). Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States. Antimicrob. Agents Chemother. 44: 2645-2652 [Abstract] [Full Text]  
  • Sahm, D. F., Peterson, D. E., Critchley, I. A., Thornsberry, C. (2000). Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States. Antimicrob. Agents Chemother. 44: 2521-2524 [Abstract] [Full Text]  
  • Pong, A., Thomson, K. S., Moland, E. S., Chartrand, S. A., Sanders, C. C. (1999). Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother 44: 621-627 [Abstract] [Full Text]  
  • MacGowan, A. P., Bowker, K. E., Wootton, M., Holt, H. A. (1999). Activity of Moxifloxacin, Administered Once a Day, against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model of Infection. Antimicrob. Agents Chemother. 43: 1560-1564 [Abstract] [Full Text]  
  • Vila, J., Ruiz, J., Sanchez, F., Navarro, F., Mirelis, B., de Anta, M. T. J., Prats, G. (1999). Increase in Quinolone Resistance in a Haemophilus influenzae Strain Isolated from a Patient with Recurrent Respiratory Infections Treated with Ofloxacin. Antimicrob. Agents Chemother. 43: 161-162 [Abstract] [Full Text]  
  • Piddock, L. J. V., Johnson, M., Ricci, V., Hill, S. L. (1998). Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory Tract. Antimicrob. Agents Chemother. 42: 2956-2960 [Abstract] [Full Text]  
  • Brenwald, N. P., Gill, M. J., Wise, R. (1998). Prevalence of a Putative Efflux Mechanism among Fluoroquinolone-Resistant Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42: 2032-2035 [Abstract] [Full Text]  
  • Ji, B., Lounis, N., Maslo, C., Truffot-Pernot, C., Bonnafous, P., Grosset, J. (1998). In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42: 2066-2069 [Abstract] [Full Text]  
  • Schmidt, H., Dalhoff, A., Stuertz, K., Trostdorf, F., Chen, V., Schneider, O., Kohlsdorfer, C., Brück, W., Nau, R. (1998). Moxifloxacin in the Therapy of Experimental Pneumococcal Meningitis. Antimicrob. Agents Chemother. 42: 1397-1401 [Abstract] [Full Text]  
  • Roblin, P. M., Hammerschlag, M. R. (1998). In Vitro Activity of a New 8-Methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 42: 951-952 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»